Laparoscopic Transhiatal Esophagectomy With Neoadjuvant Chemotherapy To Treat Carcinoma Of The Upper Esophagus | 3563
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Esophagectomy for Carcinoma of the upper esophagus has traditionally been performed by open methods.
Results from most series include mortality rates in excess of 5% and hospital stays frequently greater than 14 days. Laparoscopic
transhiatal esophagectomy (LTHE) with neoadjuvant chemotherapy has the potential to improve these results and may lead to a
sound outcome, but only a few articles have reported it.
To investigate the method of LTHE with neoadjuvant chemotherapy treating cervical esophageal cancer.
Methods: LTHE was performed in 5 patients with carcinoma of the upper esophagus. There were 4 men and 1 women. Median
age was 64 years (range, 54?75). Indications for operation included high-grade dysplasia (n = 1) and cancer (n = 4). Neoadjuvant
chemotherapy was used in 5 patients.
There was no conversion to open procedure. LTHE was successfully completed in 5 patients. The median intensive care
unit stay was 1.5 days (range, 1?3); hospital stay was 10.5 days (range, 9?13). There was no anastomotic leak case happenning.
At a mean follow-up of 13 months (range, 1?24), quality of life scores were similar to preoperative values and population norms.
LTHE with neoadjuvant chemotherapy is a safe and relatively advanced, complex procedure with little blood loss
and less-invasion. Its long-term outcome needs to be investigated with large-volume cases.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals